AAAAAA

   
Results: 1-8 |
Results: 8
First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report
Authors: Vogel, C Cobleigh, MA Tripathy, D Gutheil, JC Harris, LN Fehrenbacher, L Slamon, DJ Murphy, M Novotny, WF Burchmore, M Shak, S Stewart, SJ
Citation: C. Vogel et al., First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report, EUR J CANC, 37, 2001, pp. S25-S29
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer
Authors: Gordon, MS Margolin, K Talpaz, M Sledge, GW Holmgren, E Benjamin, R Stalter, S Shak, S Adelman, DC
Citation: Ms. Gordon et al., Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer, J CL ONCOL, 19(3), 2001, pp. 843-850
First-line Herceptin (R) monotherapy in metastatic breast cancer
Authors: Vogel, CL Cobleigh, MA Tripathy, D Gutheil, JC Harris, LN Fehrenbacher, L Slamon, DJ Murphy, M Novotny, WF Burchmore, M Shak, S Stewart, SJ
Citation: Cl. Vogel et al., First-line Herceptin (R) monotherapy in metastatic breast cancer, ONCOL-BASEL, 61, 2001, pp. 37-42
Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2.
Authors: Slamon, DJ Leyland-Jones, B Shak, S Fuchs, H Paton, V Bajamonde, A Fleming, T Eiermann, W Wolter, J Pegram, M Baselga, J Norton, L
Citation: Dj. Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastaticbreast cancer that overexpresses HER2., N ENG J MED, 344(11), 2001, pp. 783-792
Coarse spray delivery to a localized region of the pulmonary airways for gene therapy
Authors: Cipolla, DC Gonda, I Shak, S Kovesdi, I Crystal, R Sweeney, TD
Citation: Dc. Cipolla et al., Coarse spray delivery to a localized region of the pulmonary airways for gene therapy, HUM GENE TH, 11(2), 2000, pp. 361-371
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Authors: Cobleigh, MA Vogel, CL Tripathy, D Robert, NJ Scholl, S Fehrenbacher, L Wolter, JM Paton, V Shak, S Lieberman, G Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648
Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer
Authors: Shak, S
Citation: S. Shak, Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer, SEMIN ONCOL, 26(4), 1999, pp. 71-77
Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus
Authors: Harvey, BG Leopold, PL Hackett, NR Grasso, TM Williams, PM Tucker, AL Kaner, RJ Ferris, B Gonda, I Sweeney, TD Ramalingam, R Kovesdi, I Shak, S Crystal, RG
Citation: Bg. Harvey et al., Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus, J CLIN INV, 104(9), 1999, pp. 1245-1255
Risultati: 1-8 |